COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS)
Scientific title
Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients: A Prospective, Multi-center, Non-randomized, Open Label Study.
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Study type
Description of intervention(s) / exposure
Treatment: Devices - HeartPOD™ System

Experimental: HeartPOD™ System - Implantation of HeartPOD™ System

Treatment: Devices: HeartPOD™ System
HeartPOD™ device automatically measures left heart pressures throughout the day.

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Freedom from Major Adverse Cardiac and Neurological Events (MACNE) at 6 weeks.
Timepoint [1] 0 0
12 months

Key inclusion criteria
- Age > 18 and < 85.

- Documented history of congestive heart failure resulting from ischemic or non-ischemic
cardiomyopathy with systolic or diastolic dysfunction of at least 6 months duration.

- Patients with LVEF < 40% should receive maximally tolerated doses of ACE-I (or ARB if
ACE-I is not tolerated), beta blockers, and anti-aldosterone therapy. The combination
of hydralazine and nitrates should be considered in the persistently symptomatic
African American patient.

- A history of NYHA Class II (OUS only), III or IV symptoms.

- Minimum of one (1) prior hospital admission within the last 12 months for exacerbation
of CHF or one (1) presentation to the Emergency Department or Clinic requiring
parenteral diuretic, vasodilator, inotrope, nesiritide, or equivalent treatment.

- Female subjects of childbearing potential must have a negative pregnancy test within
seven (7) days before the procedure.

- Central venous vascular access.

- Capable of Valsalva maneuver with airway pressure > 40 mm Hg for 10 seconds.

- The subject and the treating physician agree that the subject will comply with all
required post-procedure follow-up, and that the patient is capable of correct device
use as outlined in the protocol.

- Written informed consent.
Minimum age
18 Years
Maximum age
85 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Intractable HF with resting symptoms despite maximal medical therapy or active listing
for cardiac transplantation (< 6 months survival expected).

- Resting systolic blood pressure < 90 or > 180 mmHg.

- Acute MI, unstable ischemic syndrome within the last 6 weeks.

- Percutaneous coronary intervention (PCI) or cardiac surgery performed or planned
within 6 weeks.

- Coexisting stenotic valve lesions, vegetations, hypertrophic cardiomyopathy,
amyloidosis or other infiltrative heart disease, constrictive, restrictive disease,
tamponade, or moderate or large pericardial effusion.

- Subject has a history of deep venous thrombosis or pulmonary embolism.

- Surgical correction of congenital heart disease involving atrial septum.

- CVA or TIA within 6 months. History of uncorrected cerebral vascular disease.

- Atrial or ventricular thrombus, tumor or systemic thromboembolism.

- Chronic atrial fibrillation.

- Symptomatic bradyarrhythmia or sustained VT/VF unless successfully treated with
cardiac rhythm management device for 6 weeks.

- Atrial septal defect or patent foramen ovale > 2 mm in diameter.

- Life expectancy < 1 year from malignancy, primary pulmonary hypertension, renal,
hepatic, or neurological condition, etc.

- Gastrointestinal bleeding during the last 6 months.

- Coagulopathy or uninterruptible anticoagulation therapy or unable to take antiplatelet

- Creatinine > 2.5 gm/dl

- Temperature > 37.8C or white blood cell count (WBC) > 13,000/mm3.

- The subject is currently participating in an investigational drug or another device
study that has not completed the primary endpoint or that clinically interferes with
the current study endpoints.

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1/Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Country [2] 0 0
United States of America
State/province [2] 0 0
Country [3] 0 0
United States of America
State/province [3] 0 0
Country [4] 0 0
New Zealand
State/province [4] 0 0
Country [5] 0 0
New Zealand
State/province [5] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Abbott Medical Devices

Ethics approval
Ethics application status

Brief summary
Most people with heart failure take a number of medications that work in different ways.
Patients and their families need to keep track of prescribed medications and follow
instructions on how much to take and when to take them. Currently, doctors are guided
primarily by symptoms. The device being studied in this trial (called the HeartPOD™ System)
monitors heart function from inside your body and alerts the patient and physician of
necessary changes to your medication.
Trial website
Trial related presentations / publications
Ritzema J, Melton IC, Richards AM, Crozier IG, Frampton C, Doughty RN, Whiting J, Kar S, Eigler N, Krum H, Abraham WT, Troughton RW. Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation. 2007 Dec 18;116(25):2952-9. Epub 2007 Dec 3.
Public notes

Principal investigator
Name 0 0
William T. Abraham, MD, FACC
Address 0 0
Ohio State University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications